ClostraBio recognized for scientific leadership in developing its next-generation probiotic, CLB101™

ClostraBio, a biotechnology company developing next-generation probiotics to support gut health, joined fellow winners of the Chicago Innovation Awards, the Chicago region’s foremost annual celebration of innovation, in New York City on Monday, August 31st to ring the Opening Nasdaq Bell. The event emphasized the breadth of innovation in the Chicago region and shined a spotlight on the organizations that make up its vibrant economy.

“Chicago Innovation Award winners cut across all industries and represent the best in new product and service development from large companies, startups and non-profits,” said Luke Tanen, President and CEO of Chicago Innovation. “Their winning innovations are solving a range of unmet needs in the marketplace, and we’re proud to celebrate their successes on a global stage by ringing the Nasdaq Bell.”

Joining ClostraBio were other winners of the 2025 Chicago Innovation Awards. The full list of 2025 winners includes Abbott, Aegis Foods, Chamberlain Group, CharCharms, ClostraBio, CloudNuro, Cultivate Collective, Cylinder Health, Ganance, GigaStar, Ignite, Latinos Progresando & Greater Auburn Gresham Development Corporation, Prenosis, (P)Rind, Medill School of Journalism at Northwestern University, Sphera, Sunshine Enterprises, Trajektory, Urban Growers Collective, Xchange Chicago and Zerno.

ClostraBio’s winning innovation is CLB101™, a unique, next-generation strain that is highly differentiated from traditional probiotics. A strict anaerobe isolated from healthy humans, CLB101™ can directly produce the short-chain fatty acid butyrate to impact gut health, barrier integrity, immunity and microbiome balance*. CLB101™ has achieved GRAS status, demonstrated clinical efficacy, and is currently marketed in the US as a dietary supplement.

“Being named a Chicago Innovation Awards winner is a wonderful acknowledgement of our team’s years of hard work in bringing CLB101™ to market, and the true innovation CLB101™ represents in the dietary supplements category,” said Ritu Shah, CEO of ClostraBio. “With the recent completion of our first clinical study and submission of the resulting manuscript to a scientific journal for peer-review, we look forward to publishing data describing how CLB101™ positively impacts human health. We sincerely appreciate the recognition from Chicago Innovation and will continue our work to help support the many people who routinely suffer from gut health challenges.”

About ClostraBio:

ClostraBio is leveraging a science driven, multi-pronged approach to address conditions of the lower gut, using novel biotechnology to harness natural pathways. The Company has commercialized a next-generation probiotic, CLB101™ that produces butyrate in the lower gut to impact intestinal barrier function and promote gut health* and is developing a novel polymeric prodrug platform designed to deliver small molecules to the lower gut. ClostraBio was spun out of the University of Chicago and is incubated at Portal Innovations.

About Chicago Innovation and the Chicago Innovation Awards

Chicago Innovation, established in 2002, has grown from a single awards ceremony to a year-round series of events and programs to educate, connect and celebrate all innovators in the Chicago region. Chicago Innovation’s vision is to lead a movement that ensures innovation is for everyone. The Chicago Innovation Awards celebrate the most innovative new products, services and organizations in the Chicago region, cutting across all industries, large corporations and startups, for profits and non-profits, high tech, low tech and no tech. For more information, visit http://www.chicagoinnovation.com.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260909408223/en/